Skip to content

Study on the therapeutic effect of Cefuroxime Axetil Tablets in the treatment of aerobic vaginitis

Study on the therapeutic effect of Cefuroxime Axetil Tablets in the treatment of aerobic vaginitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17012584
Enrollment
Unknown
Registered
2017-09-05
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aerobic vaginitis

Interventions

Cefuroxime Axetil Tablets treatment group:Cefuroxime Axetil Tablets oral

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Patients with simple AV confirmed by clinical and laboratory pathogenic examination before the test; 2. With follow-up conditions, good compliance and signed informed consent of volunteers; 3. 18-50 years of age, sexual life history, menstrual period; 4. Patients who were not treated with any oral medication in the last one month; 5. Patients who were not treated with any external drugs in the last two weeks; 6. The pregnancy test was negative in women of childbearing age, during the test can adhere to contraception and condom use in life.

Exclusion criteria

Exclusion criteria: 1. Those with fungal, viral or other microbial infections; severe cervical erosion; 2. Other diseases need to be treated with antibiotics, hormones, immunosuppressive drugs and other drugs; 3. HIV positive or abnormal immune function; 4. Patients with poorly controlled diabetes; 5. Severe liver and kidney dysfunction; combined with heart disease such as congestive heart failure, malignant arrhythmia, etc.; 6. During the test the other operation plan; 7. Pregnant and lactating women, and planned pregnancy within 3 months; 8. Allergic, or allergic to this test drug; 9. Other clinical trials in last one month; 10. Unconditional follow-up.

Design outcomes

Primary

MeasureTime frame
AV score was evaluated by wet film microscopy;Evaluation of clinical efficacy based on symptoms and signs;Onset time;Recurrence rate;

Countries

China

Contacts

Public ContactFengxia Xue

Tianjin Medical University General Hospital

fengxiaxue1962@163.com+86 15922125459

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026